Basic & Clinical Medicine ›› 2022, Vol. 42 ›› Issue (9): 1449-1453.doi: 10.16352/j.issn.1001-6325.2022.09.1449

• Mini Reviews • Previous Articles     Next Articles

Research progress on roxadustat treatment for renal anemia

HU Bao-li1, HU Bin2*   

  1. 1. Medical College of China Three Gorges University, Yichang 443002;
    2. Department of Nephrology, Affiliated Renhe Hospital of China Three Gorges University,Yichang 443000,China
  • Received:2021-04-22 Revised:2021-08-13 Online:2022-09-05 Published:2022-09-02

Abstract: Renal anemia is an independent risk factor for progression of chronic kidney disease (CKD).Roxadustat, a novel medicine for renal anemia, utilizes the body's native response to hypoxia for activating the hypoxia-induced signaling pathway, regulating endogenous erythropoietin(EPO) production and improving iron metabolism, so effectively corrects hemoglobin level and comprehensively regulates erythropoiesis.

Key words: roxadustat, renal anemia, prolyl hydroxylase inhibitor, hypoxia-inducible factor, chronic kidney disease

CLC Number: